CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
CRISPR Therapeutics's price to book ratio was 2.5× on Nov 11, 2026, against 2.6× a year earlier. Over the last 5 years it ranged from 1.5× to 3.6×, with a median of 2.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.5× | −0.0 |
| 2025 | Dec 31, 2025 | 2.6× | +0.8 |
| 2024 | Dec 31, 2024 | 1.7× | −1.1 |
| 2023 | Dec 29, 2023 | 2.9× | +1.2 |
| 2022 | Dec 30, 2022 | 1.6× | −0.7 |
| 2021 | Dec 31, 2021 | 2.3× | −5.7 |
| 2020 | Dec 31, 2020 | 8.0× | +2.4 |
| 2019 | Dec 31, 2019 | 5.7× | +2.1 |
| 2018 | Dec 31, 2018 | 3.5× | −1.8 |
| 2017 | Dec 29, 2017 | 5.3× | – |
See a number that looks wrong?